That clinical trial roadmap shows us that by mid march next year we will have the Initial Phase 1 results readout and by the end of April the final readout. Given we will have progress reports from now on how each of the 4 cohorts are tracking we will have a good idea of success before the readout.
The trial should run smoothly from here and timelines met.
Plus Phase 2 Ethics preparation by end of June.
Recce Pharmaceuticals have completed Phase 1 for their super drug R327 and have a market cap of $120 mil. That would put us at $1.37. But I would expect AGN to be much higher if everything runs smoothly.
Ann: Investor Presentation, page-3
-
- There are more pages in this discussion • 24 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AGN (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
75.0¢ |
Change
-0.020(2.60%) |
Mkt cap ! $96.06M | |||
| Open | High | Low | Value | Volume |
| 77.0¢ | 77.0¢ | 75.0¢ | $78.71K | 104.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 7000 | 74.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 77.0¢ | 9781 | 1 |
View Market Depth
| Last trade - 15.25pm 13/11/2024 (20 minute delay) ? |
| AGN (ASX) Chart |